Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brentuximab Vedotin Plus AVD in Non-bulky Limited Stage Hodgkin Lymphoma
NCT01534078Phase 2Completed
- Sponsor
- Massachusetts General Hospital
- Start
- Mar 2012
- Primary completion
- Jan 2015
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of brentuximab vedotin in Hodgkin lymphoma (HL), sponsored by Massachusetts General Hospital. Started Mar 2012; status: completed.
02
Drugs
brentuximab vedotin
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT01534078.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01534078.